| Document |
Document Title |
|
WO/2023/219127A1 |
The present invention provides a pharmaceutical composition which is for use in the treatment or prevention cystic disease and which comprises, as an active component, a compound that inhibits a phosphate transporter.
|
|
WO/2023/218804A1 |
An adipose-derived stem cells exosome and at least one component selected from the group consisting of recombinant leptin, γ-oryzanol, inulin, zinc and vitamin C are contained.
|
|
WO/2023/219361A1 |
The present invention relates to a composition comprising the compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of fibrotic diseases. The composition acco...
|
|
WO/2023/219434A1 |
Provided are endovascular transplant cells, a preparation method therefor, and a use thereof, wherein the cells have hemocompatibility as the expression or activity level of CD142, a starting factor of blood coagulation, therein is reduc...
|
|
WO/2023/220046A1 |
This disclosure relates to compounds of formula (I), or pharmaceutically acceptable salts thereof: in which all of the variables are as defined in the application. The compounds of the present disclosure are capable of inhibiting the act...
|
|
WO/2023/220561A1 |
The disclosure relates to isolated oligonucleotides comprising duplex regions targeting hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), and delivery systems, kits and compositions comprising same, and methods of using same for inhibi...
|
|
WO/2023/220357A1 |
The present disclosure provides methods for treating or preventing loss of organ function due to chronic organ or tissue diseases by administering to a subject an effective amount of a TLR4 agonist, such as an MPLA-like compound. More pa...
|
|
WO/2023/217675A1 |
To meet the needs of new therapies for preventing or treating pathological dysbiosis of the intestinal microbiota, in particular for treating or preventing neurodegenerative or intestinal diseases. The invention relates to the use of com...
|
|
WO/2023/214059A1 |
The present invention relates to a pharmaceutical composition comprising a compound of Formula (I): or a pharmaceutically acceptable salt or solvate thereof; in particular to long-acting injectables comprising the same, the use of the ph...
|
|
WO/2023/214791A1 |
The present invention relates to a composition for regenerating a pulp-dentin complex, and a method for producing same. Dental pulp stem cells cultured in the presence of garcinol can promote dentin formation by inhibiting bone different...
|
|
WO/2023/215279A1 |
The invention relates to the unexpected discovery that the oral administration of charged sodium channel blockers, also called "Nocions," alleviates inflammation in intestinal inflammatory diseases, such as inflammatory bowel disease (IB...
|
|
WO/2023/215378A1 |
Provided herein are compounds and compositions thereof for modulating hepatocyte growth factors. In some embodiments, the compounds and compositions are provided for treatment of diseases, including fibrosis.
|
|
WO/2023/215220A1 |
The present disclosure provides, in part, compounds of formula (I), or a stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein; pharmaceutical compositions comprising the compounds; a...
|
|
WO/2023/215367A1 |
Provided herein are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, R2, R3, and n are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a comp...
|
|
WO/2023/215196A1 |
Disclosed herein are autotaxin inhibitor compounds, polymorphic forms, pharmaceutical compositions, and the method of use and preparation thereof. Some embodiments relate to crystalline forms of Compound 1 and salts thereof.
|
|
WO/2023/214280A1 |
An oral dosage form for controllable release and method of forming are described. The oral dosage form includes a core layer including an active ingredient and a plurality of outer shell layers surrounding the core layer, the plurality o...
|
|
WO/2023/215478A1 |
Provided herein is a method of treating a subject with a respiratory disorder when the subject is receiving high-flow oxygen through a nasal cannula, comprising administering a pharmaceutical composition comprising a therapeutic agent (s...
|
|
WO/2023/213293A1 |
The present invention relates to a dipeptide derivative composition, a preparation method therefor, and use thereof. The composition comprises (a) a compound represented by formula I, (b) glycine, and (c) an antioxidant. The composition ...
|
|
WO/2023/214404A1 |
A mucoadhesive composition and method for the administration of the pharmaceutically effective agents is provided. Specifically, a mucoadhesive composition, composed of a mucoadhesive polymer and a plurality of active agents having diffe...
|
|
WO/2023/212773A1 |
The present disclosure is directed to the preparation of an anti-methanogenic oil composition from a biomass of red marine algae using a heterogeneous extraction liquid comprising an aqueous solution and at least one oil. The present dis...
|
|
WO/2023/214772A1 |
The present invention relates to an isobenzofuran-1(3H)-one derivative, which is a kinase inhibitor, and a use thereof and, more specifically, to an isobenzofuran-1(3H)-one derivative having HPK1 inhibitory activity and MLK3 inhibitory a...
|
|
WO/2023/213460A1 |
An oral care composition comprising: a) from 20 to 90wt% of the total composition of one or more organic polyols having 3 or more hydroxyl groups in the molecule; b) calcium silicate; c) a sodium phosphate salt; d) mono calcium phosphate...
|
|
WO/2023/213878A1 |
The present invention relates to solid tablet oral dosage forms of 2,2'-di(pyridin-4-yl)- 1H,1'H-5,5'-bibenzo[d]imidazole (which may also be known as 2,2'-di-4-pyridinyl-6,6'-bi-1H- benzimidazole, 5,5'-bis[2-(4-pyridinyl)-1H-benzimidazol...
|
|
WO/2023/211864A1 |
Methods of treating obesity, reducing body weight, or inhibiting weight gain in a subject in need thereof, the methods comprising administering to the subject a pharmaceutical composition comprising an effective amount of a large amino a...
|
|
WO/2023/210880A1 |
[Objective]: To provide a natural product-derived composition having little or no side effects and exhibiting activity to prevent, treat, or alleviate periodontal disease [Solution]: The present inventors found that ginsenoside compound ...
|
|
WO/2023/211843A1 |
The present application relates to compounds of formula (I) or (Ia) (e.g., fexuprazan), for treating pathological hypersecretory conditions, such as a condition comprising gastric acid hypersecretion (e.g., Zollinger-Ellison syndrome, id...
|
|
WO/2023/210481A1 |
A composition for treating or preventing respiratory diseases, a composition for improving sleep or promoting sleep onset, a composition for reducing fatigue, a composition for improving complexion, a composition for improving skin textu...
|
|
WO/2023/212622A1 |
Provided are compositions that include compositions of galactosyl-conjugated lipid, nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl-conjugated LNPs have a lipid component having D-Lin-MC3...
|
|
WO/2023/208068A1 |
Provided are an IMM-H014 sustained-release tablet for treating non-alcoholic fatty liver disease, hepatitis and drug-induced liver disease, and a preparation method therefor. The sustained-release tablet is prepared from an active pharma...
|
|
WO/2023/208106A1 |
The present invention provides a compound represented by formula (I), or a prodrug, a tautomer, a stereoisomer, a solvate, an isotope derivative, or a pharmaceutically acceptable salt thereof. The compound of the present invention is a n...
|
|
WO/2023/205857A1 |
The present disclosure relates to a novel compound, which is an analogue of vitamin D. The present disclosure also relates to pharmaceutical compositions including the novel compound, and to the use of the novel compound in treating and/...
|
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
|
WO/2023/211932A1 |
Provided herein is a composition including a buffering agent (e.g., a phosphate buffering agent) and an aqueous carrier, wherein the pH of the composition is maintained in a range of from 5.5 to 8.5, with a buffering strength of from 0. ...
|
|
WO/2023/208816A1 |
The present invention relates to a composition comprising a genetically engineered non-pathogenic microorganism expressing one or more polypeptide comprising polypeptide hormones. The composition is preferably for use in the treatment of...
|
|
WO/2023/283021A9 |
Diagnostic microarray devices, kits, and methods of treating or reducing the occurrence of various conditions or diseases are disclosed, wherein the conditions or diseases include (but are not limited to) periodontal disease, Alzheimer's...
|
|
WO/2023/210988A1 |
The present application relates to: a Bifidobacterium bifidum HEM972 strain (KCTC14144BP); a composition for improving the intestinal environment comprising same; and a composition for treating or preventing an intestinal disease. A Bifi...
|
|
WO/2023/210740A1 |
The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
|
|
WO/2023/211195A1 |
The present disclosure provides a compound represented by Formula (I) or a pharmaceutically acceptable salt which are effective as a sodium channel blocker and a method of using the compound.
|
|
WO/2023/186174A9 |
Provided herein is a gel composition for topical use, which comprises an IL-17 A binding molecule and suitable excipients.
|
|
WO/2023/212019A1 |
The present invention provides compounds of Formula (I), pharmaceutical compositions comprising these compounds and methods of using these compounds for treating a metabolic disease or liver condition. The present invention relates gener...
|
|
WO/2023/210723A1 |
Provided is a pharmaceutical composition that can be used to treat symptoms of an inflammatory bowel disease or relieve already developed symptoms. 5-Hydroxyindoleacetic acid or a pharmacologically acceptable salt, prodrug, conjugate o...
|
|
WO/2023/210716A1 |
[Problem] To provide a pharmaceutical composition useful for the prevention or treatment of liver disease, in particular, liver fibrosis or liver cirrhosis. [Solution] Provided is a pharmaceutical composition that is for the prevention a...
|
|
WO/2023/208076A1 |
A nucleic acid-loaded calcium-containing cationic lipid nanoparticle, comprising a cationic lipid, a neutral lipid, a PEGylated lipid, and cholesterol and/or a cholesterol ester. The cationic lipid nanoparticle can be used for preparing ...
|
|
WO/2023/208944A1 |
The invention discloses a pharmaceutical or dietary supplement composition comprising a particular combination of compounds including histidine, serine, cysteine and carnosine. The compositions are proposed as ingredients in food product...
|
|
WO/2023/205650A1 |
The present invention describes methods of detecting IBS-D. Further described are methods selecting a therapy and methods of treatment for IBS-D. These methods are based, at least in part, on a subject's level of Desulfovibrio, Fusobacte...
|
|
WO/2023/205368A1 |
The disclosure relates to methods for increasing gastric emptying in a human having gastroparesis.
|
|
WO/2023/202353A1 |
The present invention belongs to the technical field of microorganisms. Disclosed is a bifidobacterium longum CCFM1206 strain for producing sulforaphane and capable of relieving inflammation. The bifidobacterium longum CCFM1206 provided ...
|
|
WO/2023/204562A1 |
The present invention relates to a composition for treating colitis, comprising a flagellin and immunoglobulin Fc fusion protein and, more specifically, to a composition for treating colitis, which is a fusion protein comprising flagelli...
|
|
WO/2023/204564A1 |
The present invention relates to a composition comprising a flagellin and immunoglobulin Fc fusion protein for the treatment of liver disease or metabolic syndrome and, more specifically, concerns a composition comprising a fusion protei...
|
|
WO/2023/202582A1 |
A compound of a GPR132 regulator, a pharmaceutically acceptable salt or ester, a prodrug, a stereoisomer, a hydrate, a solvate, a crystal form, or a metabolite form thereof, as well as a preparation method therefor and medicinal use ther...
|
